Gene expression profiles of inflammatory breast cancer reveal high heterogeneity across the epithelial-hybrid-mesenchymal spectrum

Simple item page
dc.citation.articleNumber101026en_US
dc.citation.issueNumber4en_US
dc.citation.journalTitleTranslational Oncologyen_US
dc.citation.volumeNumber14en_US
dc.contributor.authorChakraborty, Priyankaen_US
dc.contributor.authorGeorge, Jason Ten_US
dc.contributor.authorWoodward, Wendy Aen_US
dc.contributor.authorLevine, Herberten_US
dc.contributor.authorJolly, Mohit Kumaren_US
dc.contributor.orgCenter for Theoretical Biological Physicsen_US
dc.date.accessioned2021-02-24T19:15:39Zen_US
dc.date.available2021-02-24T19:15:39Zen_US
dc.date.issued2021en_US
dc.description.abstractInflammatory breast cancer (IBC) is a highly aggressive breast cancer that metastasizes largely via tumor emboli, and has a 5-year survival rate of less than 30%. No unique genomic signature has yet been identified for IBC nor has any specific molecular therapeutic been developed to manage the disease. Thus, identifying gene expression signatures specific to IBC remains crucial. Here, we compare various gene lists that have been proposed as molecular footprints of IBC using different clinical samples as training and validation sets and using independent training algorithms, and determine their accuracy in identifying IBC samples in three independent datasets. We show that these gene lists have little to no mutual overlap, and have limited predictive accuracy in identifying IBC samples. Despite this inconsistency, single-sample gene set enrichment analysis (ssGSEA) of IBC samples correlate with their position on the epithelial-hybrid-mesenchymal spectrum. This positioning, together with ssGSEA scores, improves the accuracy of IBC identification across the three independent datasets. Finally, we observed that IBC samples robustly displayed a higher coefficient of variation in terms of EMT scores, as compared to non-IBC samples. Pending verification that this patient-to-patient variability extends to intratumor heterogeneity within a single patient, these results suggest that higher heterogeneity along the epithelial-hybrid-mesenchymal spectrum can be regarded to be a hallmark of IBC and a possibly useful biomarker.en_US
dc.identifier.citationChakraborty, Priyanka, George, Jason T, Woodward, Wendy A, et al.. "Gene expression profiles of inflammatory breast cancer reveal high heterogeneity across the epithelial-hybrid-mesenchymal spectrum." <i>Translational Oncology,</i> 14, no. 4 (2021) Elsevier: https://doi.org/10.1016/j.tranon.2021.101026.en_US
dc.identifier.digital1-s20-S1936523321000188-mainen_US
dc.identifier.doihttps://doi.org/10.1016/j.tranon.2021.101026en_US
dc.identifier.urihttps://hdl.handle.net/1911/110076en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsThis is an open access article under the CC BY-NC-ND licenseen_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.titleGene expression profiles of inflammatory breast cancer reveal high heterogeneity across the epithelial-hybrid-mesenchymal spectrumen_US
dc.typeJournal articleen_US
dc.type.dcmiTexten_US
dc.type.publicationpublisher versionen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
1-s20-S1936523321000188-main.pdf
Size:
2.25 MB
Format:
Adobe Portable Document Format
Download
Collections
Faculty Publications
Test Environmental Research Collection